Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

FDA OKs Novartis’ Pancreatic Tumor Drug

By Drug Discovery Trends Editor | May 6, 2011

 The U.S. Food and Drug Administration (FDA) approved Novartis’ drug Afinitor for treating patients with advanced neuroendocrine tumors originating in the pancreas.

The approval was based on data from a drug trial that showed Afinitor more than doubled the time patients went without tumor growth. It also was found to reduce the risk of cancer progression by 65% compared with patients taking placebo. The move represents the first approval of a treatment for this condition in the United States in nearly 30 years.
Afinitor is approved as a treatment for advanced kidney cancer, as well as for children and adults with a benign brain tumor associated with tuberous sclerosis, a rare genetic disorder, which causes tumors in the brain, eyes, lungs, liver and other organs.

Neuroendocrine tumors (NET) – mostly found in the pancreas, gastrointestinal tract or lungs, have limited treatment options for patients with the disease. When pancreatic NET becomes advanced, it is considered aggressive and difficult to treat. About 60% of pancreatic NET patients are diagnosed with advanced disease, and the five-year survival rate for these patients is 27%.Afinitor tablets, taken once a day, target mTOR, a protein that regulates the growth of tumor cells and the blood vessels that feed them. “With this approval, U.S. physicians can now offer their patients with progressive pancreatic NET a new treatment helping to fulfill a critical unmet need,” said Herve Hoppenot, president of Novartis Oncology.

Release Date: May 5, 2011
Source:  Novartis 


Filed Under: Drug Discovery

 

Related Articles Read More >

Tiffany Hurd
CB Therapeutics biz dev lead sees upside for psychedelics in mental health and beyond
Pharmacovigilance
A new era of pharmacovigilance: Worldwide master key for drug safety monitoring
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50